Scynexis SCYX
NASDAQ SCYX
$5.22 +0.07 (+1.36%)
At close: Aug 20, 2026 · 4:00 PM EDT

Scynexis (SCYX) Cash from Financing Activities (2013 - 2026)

Scynexis' (SCYX) quarterly Cash from Financing Activities came in at $24.0 million in Q1 2026, up 270.68% YoY from $6.5 million in Q1 2025, and up 21002.61% on a QoQ basis from -$115000.0 in Q4 2025.

Scynexis (SCYX) Cash from Financing Activities (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has 14 years of Cash from Financing Activities data on file, last reported at $24.0 million in Q1 2026.

  • Quarterly Cash from Financing Activities rose 270.68% year-over-year to $24.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.0 million (up 268.58% YoY) and the FY2025 annual result came in at -$14.2 million, down 10094.24% from the prior year.
  • Cash from Financing Activities advanced to $24.0 million in Q1 2026, from -$115000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $42.1 million in Q2 2022 to a low of -$36.6 million in Q2 2023.
  • A 5-year average of $1.5 million and a median of $3500.0 in 2023 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 9569.01% — and 2025, when it plunged 93793.33%.
  • Tracing SCYX's Cash from Financing Activities over 5 years: stood at -$183000.0 in 2022, then grew by 26.23% to -$135000.0 in 2023, then dropped by 14.81% to -$155000.0 in 2024, then increased by 25.81% to -$115000.0 in 2025, then jumped by 21002.61% to $24.0 million in 2026.
  • The last three Cash from Financing Activities figures came in at $24.0 million (Q1 2026), -$115000.0 (Q4 2025), and $29000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn -1.00 Mn
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn -813.00 Mn
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn -1.13 Bn
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn 122.40 Mn
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn -1.24 Bn
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn 63.40 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn -74.00 Mn
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - -
10 Scynexis 61.37 Mn -53.33 Mn - 13.46 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 13.46 Mn
Jun 30, 2026 13.46 Mn
Mar 31, 2026 24.04 Mn
Mar 31, 2026 24.04 Mn
Dec 31, 2025 -115,000.00
Dec 31, 2025 -115,000.00
Sep 30, 2025 29,000.00
Sep 30, 2025 29,000.00
Mar 31, 2025 -14.08 Mn
Mar 31, 2025 -14.08 Mn
Dec 31, 2024 -155,000.00
Dec 31, 2024 -155,000.00
Sep 30, 2024 31,000.00
Sep 30, 2024 31,000.00
Mar 31, 2024 -15,000.00
Mar 31, 2024 -15,000.00
Dec 31, 2023 -135,000.00
Dec 31, 2023 -135,000.00
Sep 30, 2023 34,000.00
Sep 30, 2023 34,000.00